{
  "docId": "019dd923-5fed-74f2-a96f-6b553a5d9cee",
  "docSlug": "bi-b4800d178bbbc7a4",
  "documentTitle": "ImCheck Therapeutics pitch deck used to raise Series C",
  "authorId": "Pitchdecks",
  "authorName": "ImCheck Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.331,
  "pageNumber": 2,
  "pageCount": 14,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a vertical process-style chevron list to organize four key pillars of the business.",
  "elementsJson": [
    "process_diagram",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fed-74f2-a96f-6b553a5d9cee/2",
  "deckHref": "/decks/019dd923-5fed-74f2-a96f-6b553a5d9cee",
  "deckJsonHref": "/decks/019dd923-5fed-74f2-a96f-6b553a5d9cee.json",
  "deckAnchorHref": "/decks/019dd923-5fed-74f2-a96f-6b553a5d9cee#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.15,
        "x": 0.02,
        "y": 0.0017
      },
      "kind": "diagram",
      "text": "Biological Platform & mAbs; Clinical Stage; Multiple Catalysts; Solid Foundation",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce70412c-d0ff-44ae-8e0d-062d45c59994",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.17,
        "y": 0.2
      },
      "kind": "list",
      "text": "Novel mechanisms with potential for both stand-alone & combination treatments in i/o and beyond; Targeting butyrophilins, a superfamily of novel targets - with monoclonal antibodies; Focused on unmet needs in oncology, targeting solid tumors & heme malignancies; Initiated expansion in auto-immune & infectious diseases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c6d94c8-69e6-4e3f-9370-e28c027c116c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.17,
        "y": 0.38
      },
      "kind": "list",
      "text": "Pipeline-in-product opportunity with lead program ICT01; First-in-class anti-BTN3A, γ9δ2 T cells activating mAb; Clinically demonstrated safety, mAb activity and first patient responses; Poised for test in multiple combinations in solid tumors & heme",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "673a5976-21f1-4f87-8af6-2845ec090134",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.17,
        "y": 0.55
      },
      "kind": "list",
      "text": "Pipeline-in-a-product with rapid indication expansion potential & newsflow; EVICTION trial in monoTx in solid & heme + combination with pembrolizumab in solid tumors; EVICTION expansion phase currently recruiting in two solid tumor indications; EVICTION-2 study testing ICT01 + LDSC IL-2 in solid tumors (massive/safe gd2T expansion); Multiple combinations being evaluated with/out partners (CPIs, Cytokines, CellTx, ChemoTx, ect.)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d3c8e9e-ddd0-4575-b97f-d3362caa64fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.17,
        "y": 0.78
      },
      "kind": "list",
      "text": "Positioned for growth; Strong base of investors; Experienced management team; Potential for partnering pipeline of later-stage preclinical programs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "849d27a0-3bb8-4df3-aad0-3dcb1a3ef343",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Unlocking the Power of Butyrophilins",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b1d90f3-8770-45f5-b5ca-966ccc2aad78",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "6a2bdf52-5d25-44ca-bb3a-92f388cec69e",
      "evidence": "The slide is titled 'Unlocking the Power of Butyrophilins' and contains a list of bullet points",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 2,
      "from": 2,
      "beatId": "44e0f8e4-b2ee-4a4d-8843-514ab118fec7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slide 2 introduces the company's solution, unlocking the power of butyrophilins",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}